Nifty
Sensex
:
:
14529.15
49099.99
-568.20 (-3.76%)
-1939.32 (-3.80%)

Pharmaceuticals & Drugs - Global

Rating :
50/99

BSE: 532523 | NSE: BIOCON

390.20
26-Feb-2021
  • Open
  • High
  • Low
  • Previous Close
  •  393.95
  •  401.85
  •  387.00
  •  397.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5197606
  •  20417.40
  •  487.75
  •  235.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 46,800.00
  • 76.63
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 48,426.80
  • N/A
  • 6.63

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.91%
  • 10.59%
  • FII
  • DII
  • Others
  • 17.65%
  • 6.00%
  • 4.18%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.43
  • 13.72
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.97
  • 10.36
  • 8.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 8.01
  • 30.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.71
  • 43.79
  • 55.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.48
  • 5.61
  • 6.37

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.82
  • 25.02
  • 27.92

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
1,851.00
1,716.80
7.82%
1,744.80
1,567.30
11.33%
1,671.30
1,458.90
14.56%
1,581.00
1,528.80
3.41%
Expenses
1,451.50
1,272.60
14.06%
1,353.40
1,164.50
16.22%
1,258.00
1,021.40
23.16%
1,262.40
1,125.80
12.13%
EBITDA
399.50
444.20
-10.06%
391.40
402.80
-2.83%
413.30
437.50
-5.53%
318.60
403.00
-20.94%
EBIDTM
21.58%
25.87%
22.43%
25.70%
24.73%
29.99%
14.01%
14.01%
Other Income
27.90
35.80
-22.07%
15.50
38.40
-59.64%
18.30
24.10
-24.07%
63.10
28.20
123.76%
Interest
4.80
17.70
-72.88%
6.50
13.80
-52.90%
12.50
16.60
-24.70%
16.80
15.90
5.66%
Depreciation
186.30
144.00
29.38%
177.70
131.60
35.03%
166.80
124.20
34.30%
152.40
119.80
27.21%
PBT
236.30
318.30
-25.76%
222.70
363.30
-38.70%
252.30
320.80
-21.35%
212.50
295.50
-28.09%
Tax
48.90
84.80
-42.33%
22.30
100.10
-77.72%
80.90
85.20
-5.05%
45.00
40.90
10.02%
PAT
187.40
233.50
-19.74%
200.40
263.20
-23.86%
171.40
235.60
-27.25%
167.50
254.60
-34.21%
PATM
10.12%
13.60%
11.49%
16.79%
10.26%
16.15%
7.11%
7.11%
EPS
1.41
1.69
-16.57%
1.41
1.80
-21.67%
1.25
1.72
-27.33%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
6,848.10
6,367.20
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
Net Sales Growth
9.19%
15.46%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
 
Cost Of Goods Sold
6,277.00
2,052.20
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
Gross Profit
571.10
4,315.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
GP Margin
8.34%
67.77%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
Total Expenditure
5,325.30
5,110.20
4,390.60
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
Power & Fuel Cost
-
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
% Of Sales
-
3.87%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
Employee Cost
-
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
% Of Sales
-
22.91%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
Manufacturing Exp.
-
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
113.20
81.60
% Of Sales
-
13.58%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
5.43%
4.52%
General & Admin Exp.
-
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
82.40
% Of Sales
-
2.86%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.47%
4.56%
Selling & Distn. Exp.
-
270.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
% Of Sales
-
4.25%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
Miscellaneous Exp.
-
36.10
37.20
47.40
41.00
45.30
72.70
61.80
52.90
256.70
62.40
% Of Sales
-
0.57%
0.67%
1.15%
1.05%
1.35%
2.35%
2.15%
2.13%
12.30%
52.09%
EBITDA
1,522.80
1,257.00
1,123.80
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
EBITDA Margin
22.24%
19.74%
20.38%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
Other Income
124.80
507.50
414.30
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
Interest
40.60
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
Depreciation
683.20
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
PBT
923.80
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
Tax
197.10
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
Tax Rate
21.34%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
PAT
726.70
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
PAT before Minority Interest
664.20
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
Minority Interest
-62.50
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
PAT Margin
10.61%
12.20%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
PAT Growth
-26.37%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
 
EPS
6.06
6.48
7.54
2.93
4.97
4.41
4.15
3.45
4.24
2.85
3.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
Share Capital
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,997.00
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
Non-Current Liabilities
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
Secured Loans
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
Unsecured Loans
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
Long Term Provisions
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
Current Liabilities
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
Trade Payables
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
Other Current Liabilities
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
Short Term Borrowings
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
Short Term Provisions
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
Total Liabilities
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
Net Block
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
Gross Block
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
Accumulated Depreciation
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
Non Current Assets
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
Capital Work in Progress
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
Non Current Investment
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
Long Term Loans & Adv.
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
Other Non Current Assets
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
Current Assets
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
Current Investments
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
Inventories
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
Sundry Debtors
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
Cash & Bank
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
Other Current Assets
809.20
525.50
373.30
395.80
300.70
171.60
157.60
136.90
114.30
56.70
Short Term Loans & Adv.
265.60
153.10
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
Net Current Assets
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
Total Assets
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
798.50
PBT
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
395.20
447.10
Adjustment
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
144.80
163.50
Changes in Working Capital
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
269.20
Cash after chg. in Working capital
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
879.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
-81.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
-314.50
Net Fixed Assets
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
Net Investments
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
Others
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
-112.27
Cash from Financing Activity
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
-274.60
Net Cash Inflow / Outflow
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
209.40
Opening Cash & Equivalents
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
139.90
Closing Cash & Equivalent
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
54.97
50.17
42.59
39.74
33.61
26.93
24.21
21.59
18.16
16.25
ROA
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
ROE
14.26%
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
ROCE
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
Fixed Asset Turnover
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
Receivable days
72.10
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
Inventory Days
70.72
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
Payable days
80.65
81.98
87.98
78.68
71.28
58.15
55.73
65.24
70.25
70.62
Cash Conversion Cycle
62.18
54.04
58.07
50.48
62.59
70.42
62.29
62.99
81.79
100.29
Total Debt/Equity
0.40
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
Interest Cover
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40

News Update:


  • Biocon’s arm enters into partnership with International Diabetes Federation
    16th Feb 2021, 09:38 AM

    This important partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin

    Read More
  • Biocon’s arm, Viatris receive European Commission approval for Kixelle
    12th Feb 2021, 09:24 AM

    The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the EEA countries Iceland, Liechtenstein and Norway

    Read More
  • Biocon reports 18% fall in Q3 consolidated net profit
    22nd Jan 2021, 11:30 AM

    Total income of the company increased by 7.21% at Rs 1878.90 crore for Q3FY21

    Read More
  • Biocon’s arm receives Rs 555 crore capital injection from ADQ
    8th Jan 2021, 09:08 AM

    Post the completion of this transaction, Biocon will hold 89.89% stake in Biocon Biologics on a fully diluted basis

    Read More
  • Biocon launches Tacrolimus capsules in US
    28th Dec 2020, 16:51 PM

    The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects commitment to continually evaluate and expand portfolio of complex products to serve patients

    Read More
  • Biocon’s arm signs MoU with CSSC for Mission 10 cents
    16th Dec 2020, 08:52 AM

    Tanzania will be the first country in Africa that will benefit from this collaboration between Biocon Biologics and CSSC

    Read More
  • Biocon’s arm raises Rs 1125 crore through OCDs
    10th Dec 2020, 11:22 AM

    The company has allotted 1,125 OCDs having face value of Rs 1 crore each

    Read More
  • Biocon enters into agreement to acquire stake in HRTPL
    23rd Nov 2020, 15:55 PM

    HRTPL was incorporated on September 25, 2020, which will engage in the business of power generation

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.